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MARKER CHARACTERIZATION OF ECP-INDUCED MONOCYTE-DERIVED
DENDRITIC CELLS
K Liu, E Robinson, R Filler, J Lewis, R Tigelaar and R Edelson, M Girardi.
Department of Dermatology, Yale University School of Medicine, New Haven, CT

Extracorporeal photopheresis (ECP) in the treatment of cutaneous T-cell lymphoma,
GVHD and autoimmune conditions continues to spur the question of how ECP is capable
of inducing immunogenicity and tolerance. We previously demonstrated that ECP
treatment leads to large-scale conversion of peripheral blood monocytes into functionally
competent leukocytes with dendritic cell phenotypes, which may play key roles in the
immunomodulatory capabilities of ECP. To characterize this population of cells on a
molecular level, we assessed for differential surface expression of selected gene-products
on monocytes after treatment with a model-ECP apparatus. Five gene-products
(CXCL16, SIRPa, ICAM1, TNFR1, PLAUR) showed significant increases in surface
expression after model-ECP treatment as compared to PBMC (p <0.01 for all). To
identify transcription factors (TFs) expressed by ECP-treated monocytes but not
peripheral blood monocytes, rtPCR was performed. Interactions with platelets during
ECP passage was also assessed by using model-ECP plates coated with low- and highdensity platelets. Seven TFs demonstrated increases in mRNA after passage through the
model-ECP plate (ΔRQ range 1.35- 6.78). Increased platelet density induced directional
changes in expression (RQ < 0.5) for VDR, NFkB2, CDKN1A and BCL3. In summary,
passage through the ECP plate apparatus caused activation of novel surface molecules
and transcription factors that define and characterize a unique subset of “physiologicallyinduced” DCs.
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Preface
I conceptualized this thesis as a movie with three side-reels. The over-riding
theme of all four is the goal towards the improved treatment of CTCL, as approached
from two sides: the study of photopheresis and the analysis of peripheral blood subsets in
CTCL. Within the latter, we attempted to harness information from two different, but
equally important, cellular compartments: malignant T cells vs. normal immune cells
(such as T cells and dendritic cells). From the malignant T cell compartment, we sought
to better understand the pathogenesis of CTCL with the goal of discovering novel
therapeutic targets. From the dendritic cell side, we investigated aspects of fundamental
biology also with the goal of discovering novel immunotherapeutics. By accessing the
blood of patients and healthy subjects, much was learned about the impact of these
cellular compartments on the immune system, and the potential to harness them to
improve the treatment of CTCL. I hope you enjoy the feature presentation.
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I. Introduction
Extracorporeal photopheresis: an immunomodulatory chameleon

Extracorporeal photopheresis (ECP) is an immunotherapy initially developed in the
1980’s by Dr. Richard Edelson et al. for the treatment of cutaneous T cell lymphoma
(CTCL).1 The usage of ECP has since expanded to include the treatment of chronic and
acute GVHD, prophylaxis and treatment of solid-organ transplant and several
autoimmune diseases, such as systemic sclerosis.2-4 ECP is performed via collection of
leukocytes from a patient using a leukopheresis device, which centrifuges whole blood to
produce a leukocyte-rich fraction. The buffy coat is then mixed with liquid 8-MOP, a
photosensitizing agent, and passed through a thin plastic apparatus that allows exposure
to controlled-doses of UVA radiation. The compound 8-MOP is biologically inert in the
absence of UVA, and once photoactivated, remains reactive for only microseconds,
thereby making ECP an exceptionally safe and directable form of chemotherapy.5 Due to
its efficacy in the treatment of CTCL and its extremely favorable side-effect profile, the
US Food and Drug Administration expeditiously approved ECP for the treatment of
advanced CTCL in 1988. Since its inception, the efficacy of ECP has been studied in
numerous uncontrolled trials for the treatment of mycosis fungoides (MF), the most
common variant of CTCL, and Sézary syndrome (SS), a form of CTCL with malignant T
cell involvement of the peripheral blood. With high rates of clinical skin improvement,
total remission and a remarkably low toxicity profile,6 ECP has become the
recommended first-line therapy for advanced CTCL, particularly in patients with
circulating malignant T cells in the peripheral blood.2,3,7
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Despite its efficacy and clinical applicability, the mechanism of action of ECP remains
not well elucidated and a heated focus of on-going research. Early hypotheses attributed
the effects of ECP to the destruction of malignant lymphocytes after exposure to 8-MOP
plus UVA. While this certainly induces apoptosis of cells, it is not sufficient to explain
the widespread effect of ECP since only 5-10% of total lymphocytes pass through the
treatment apparatus.8 Furthermore, ECP’s remarkable immunogenic effects in treating
malignant diseases must be also explained in the context of tolerogenic effects seen in the
treatment of GVHD and numerous autoimmune conditions.9

The roles of lymphocyte apoptosis, antigen-presenting cells and regulatory T cells

Treatment of the peripheral blood mononuclear cells (PBMC) with 8-MOP and UVA
leads to large scale apoptosis of lymphocytes through the Fas/FasL and Bcl-2 related
pathways.9 This results in the activation of apoptotic proteases leading to the
disintegration of lymphocytes and increased apoptotic fragment uptake by antigen
presenting cells. ECP-treated monocytes, however, appear largely resistant to apoptosis;
they are driven to take on more immature dendritic cell-like phenotypes as well as release
cytokines such as IL-10 and TNF-α.10-12 Current evidence points to antigen-presenting
cells (APC) as playing a major role in the induction of tolerance, as ECP-treated APCs,
such as dendritic cells (DC), phagocytose apoptotic lymphoid fragments and present the
antigen to T cells without costimulation from a true “danger” signal. Studies have shown
that the maturation state of DCs as well as the cytokine milieu greatly influences the
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generation of the local immune response. The presence or lack of an inflammatory
environment and the presence of mature vs. immature dendritic cells can skew the
development towards an immunostimulatory or immunosuppressive state.13 Surveillance
of the immune system by regulatory T cells (Treg) is not studied in this thesis but deserve
mention as another key player in ECP-induced immune modulation. The population of
CD4+CD25+ regulatory T cells is increased after ECP along with high expression levels
of CD45RO and Foxp3, a finding suggestive of how ECP might dampen autoimmune
responses and induce immune tolerance.14,15

Pathways of T cell co-stimulation

The complex mechanisms of T cell co-stimulation may also serve to explain how ECP is
able to establish central and peripheral self-tolerance for the treatment of GVHD and
autoimmunity.13 Naïve CD4+ and CD8+ T cells require activation before acquiring
effector functions, and this process is stringently regulated to ensure purposeful
activation, and requires several signals. The first signal involves the engagement of a
major histocompatibility complexes (MHC) on APCs with T cell receptors (TCR) on T
cells, which generates a specific signal involving the CD3 complex.16 Additional costimulatory signals are generated through other cell surface molecules, and lastly,
cytokines produced by APCs also influence T cell activation.17,18 These three signaling
pathways work together to induce T cell activation and the accompanying gene
transcription, which leads to clonal expansion and differentiation of antigen-specific T

	
   3	
  

	
  
cells. Conversely, the lack of co-stimulatory molecules or purposeful suppression of
these pathways leads to T cell anergy and immunosuppression.

Examples of co-stimulatory pairs involved in T cell activation include CD28:CD80/86,
CTLA-4:CD80/CD86, PD-1:PD-L1/2, CD40:CD154 and several others. The classic axis
of CD28:CD86 regulated T cell activation is very well characterized in the literature.
Conversely, CTLA-4 also binds CD80/CD86, with even higher affinity, and in turn
inhibits the T cell response by limiting interactions with CD28. This decreases
inflammatory cytokine secretion as well as suppresses clonal T cell expansion, and a
CTLA4-Ig fusion protein has been developed specifically to inhibit this pathway of costimulation in allograft rejection.19-21 Similar to CTLA4, PD-1 also possesses inhibitory
activity and plays an important role in suppressing T cell activation. The PD-1 doubleknockout mouse model has the propensity to develop autoimmunity, demonstrating the
importance of PD-1 in the maintenance of central and peripheral tolerance. Similarly,
blocking antibodies against PDL1 results in increased antigen-specific T cell expansion
and differentiation.22-24 LFA-1:ICAM interaction belongs to a family of wellcharacterized integrin pathways involved in T cell migration, T cell and APC interactions
and the provision of co-stimulatory signals. LFA-blocking antibodies used in animal
models have shown prolongation in the survival time of several solid organ transplants,
demonstrating the importance of ICAM co-stimulation in T cell clonal expansion.25-27
The activities of these co-stimulatory pathways highlight the diversity of molecules
involved in all stages of the immune response, as well as the pivotal role of APCs in
promoting or suppressing T cell activation/differentiation and cytokine production16.
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Within this complex yet specific network of signaling molecules may lie the answer to
how ECP is able to enhance or attenuate the immune response.

Dendritic cells: key players in adaptive immunity

The understanding of dendritic cell physiology has evolved tremendously since their first
observation in the skin by Paul Langerhans. They are known for their unparalleled
activity as “sentinel” cells” that bridge the innate and adaptive immune systems.28
Dendritic cells are not only capable of stimulating naïve T cells in the presence of danger
signals, but they also interact with T cells on a continuous basis in the absence of foreign
antigen to enforce peripheral T-cell tolerance.29,30 In humans, DCs can originate from
lymphoid and myeloid lineages. “Classical” DCs (cDCs) are considered to be those
derived from myeloid committed CD34+ progenitor cells, and monocyte-derived DCs
(mDCs) can also form in the presence of GMCSF and ILF-4 ± TNFα. These DCs, when
mature, are known as interstitial DCs, which can activate naïve CD4+ and CD8+ T cells
as well as induce differentiation of naïve B cells. DCs that originate from CD34+ cells
committed to the lymphoid lineage, on the other hand, become plasmacytoid DCs
(pDCs). They are adept at cytokine secretion, especially interferon α/β, although they are
also capable of antigen presentation in the presence of inflammation or infection.31,32
Studies of innate or acquired DC loss provide insight into the complex roles they play in
immunity and tolerance, since T cells receive negative, tolerizing signals from DCs but
also require a “baseline” signaling through the TCR from DCs for survival. This push-
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and-pull balance of interaction between T cell and DCs may fundamentally be the
question at hand when analyzing the seemingly opposite therapeutic responses induced
by ECP. Take for example DC-specific deletion of αvβ8 integrin (requisite for TGFβ
activity on T cells) or A20 (NFκB pathway negative regulator), both of which can lead to
widespread activation of the immune system. Alterations in gene expression either due to
experimental manipulation, or due to therapeutic treatment, could alter the complex roles
of DC in T cell homeostasis and immune-modulation. The type of immune response
elicited is likely quite nuanced, depending on the activation state and class of dendritic
cell, their maturation status as well as the cytokine milieu in which these DC-T cell
interactions occur.33 It is these complexities that make dendritic cell immunobiology a
particularly worthwhile area of investigation in better understanding the efficacy of ECP,
as it applies to both tolerance induction and anti-cancer immunization.

Effects of ECP on monocyte to dendritic cell maturation

Previous work performed by the late Dr. Berger identified an interesting phenomenon
that occurred after the ECP processing of peripheral blood monocytes: these cells
underwent large-scale conversion into leukocytes with dendritic cell phenotypes.34 This
prompted a more in-depth look at these newly formed DCs, which may possess
augmented antigen-presenting functions that enhance the anti-tumor response after ECP.
The results demonstrated ECP’s ability to rapidly generate functionally competent DCs
using monocytes derived from CTCL patients and healthy subjects, without the addition
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of cytokines or multi-day culture. Furthermore, the results support the premise that ECP
treatment induced significant changes in gene expression, including many genes
associated with DC differentiation and function. The number of genes with altered
expression after ECP treatment was substantial: 498 upregulated and 631 down-regulated
genes were found in common between patients and normal subjects.

Characterization of ECP-induced monocyte-derived DCs using surface molecule
expression and transcription factor expression

The study by Berger et al. made available a vast number of candidate genes amongst the
upregulated subgroup that may serve to better define and characterize these ECP-induced
DCs, as well as shed light on aspects of their functionality. Our collaborator, Dr. Lieping
Chen, also provided a list of human transmembrane genes for cross-comparison usage.

DCs can also be divided into multiple subtypes with defining functions and
characteristics.35 Furthermore, states of infection or inflammation can induce additional
subsets of DCs from peripheral blood monocytes, which can be quite different
functionally and molecularly.36 While the identification of various DC subsets using
surface markers is useful, the redundancy of certain markers on other myeloid cell
lineages and the variability of surface expression secondary to numerous internal and
external factors can make distinguishing these subsets difficult. Therefore, it is often
necessary to make these distinctions using patterns of surface expression rather than a
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single marker. Recent studies suggest that the identification of specific DC subsets may
require the analysis of surface phenotype, in addition to the identification of lineagespecific transcription factors.37-39 In a study by Satpathy et al., a transcription factor (TF)
belonging to the BTB-ZF (Broad complex, Tramtrack, Bric-à-brac, and Zinc finger)
family, was identified as being specifically expressed in classical DCs.37 Furthermore,
using this TF, cDCs were distinguishable from all other immune lineages. Given the
unique process of producing monocyte-derived DCs using ECP treatment, we wanted to
perform in silica analysis of ECP-induced upregulated genes in search of potentially
novel, defining transcription factors that may enable examination of further functional
properties of these cells. Thus, we begin this assessment of unique surface molecule
expression and transcription factor expression with the ultimate goal of defining and
characterizing ECP-induced monocyte-derived DCs. This project fits nicely within a
larger endeavor to better understand the efficacy of ECP, likely mediated in large part
through dendritic cells, and will provide important insight into defining a process of
developing more “physiologic” DCs for use in many other branches of research.
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II. Statement of Purpose
We aimed to utilize a tabletop apparatus, the Glycotech flow chamber, as a model for the
ECP UV-exposure plate, to assess the effect of plate-passage on peripheral blood
monocytes. Previous work has shown that treatment of monocytes with the ECP plate
led to the generation of maturationally-synchronized, functionally-competent leukocytes
with dendritic cell phenotype. Our central hypothesis is that the passage of monocytes
through the Glycotech chamber induces activation of specific, novel surface molecules
that define this population of monocyte-derived dendritic cells. We plan to accomplish
this objective of identifying markers of global monocyte activation using flow cytometry
to compare the differential expression of selected, surface candidate genes, with the goal
of determining whether this differential expression alters the immuno-modulatory effects
of these monocyte-derived dendritic cells and contribute to the overall efficacy of ECP.
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III. Methods
In silica analysis of differentially expressed DC genes after ECP treatment
Previous analysis of the ECP-induced monocyte transcriptome (performed within our
department) revealed activation or suppression of >1000 genes common to ECPprocessed monocytes from patients and healthy subjects. Raw data from this analysis
was obtained, and samples separated into 1) PBMC obtained from the ECP machine pretreatment, and 2) post ECP treatment after overnight incubation in a platelet storage bag
with RPMI 1640 and 15% AB serum. Fold change in expression was calculated as ratio
= (Average pre-ECP expression)/(Average post-ECP expression) for both health control
and patient cohorts. Differential gene expression was considered as >2 fold change and a
p value of <0.05. Only genes with net positive >2 fold change (upregulated genes) were
chosen for further analysis, resulting in a list of 466 genes.

Using a database of 1950 full-length human transmembrane genes with immunologic and
hematopoietic cell surface expression (courtesy of Dr. Lieping Chen, Department of
Biological and Biomedical Sciences, Yale University; full table available as supplemental
material40), the list of 466 upregulated genes were cross-referenced to produce cell
surface, “ECP-activated” genes shared between these two datasets. To further select for
genes likely to be unique to ECP-induction, five available expression profiles of human
monocyte derived DCs grown in GMCSF and IL-4 were obtained. Lists of upregulated
genes between immature dendritic cells (after 3-7 days of culture) and elutriated
monocytes were obtained from these expression profiles and individually compared to
the list of 87 “ECP-activated” genes to produce genes unique to ECP induction.
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An extensive literature search was performed to assess the function of these genes and
their relationships to immunologic pathways. Furthermore, the raw data from the original
transcriptome analysis was recalculated to show exact numeric value of expression
change. Using these two strategies, genes were prioritized based on highest levels of
differential expression after ECP treatment and/or interesting gene function to begin in
vivo analysis in batches.

Physiologic generation of human monocyte-derived DCs
Written informed consent was obtained from all subjects in accordance with the
Declaration of Helsinki. The Yale Human Investigational Review Board approved the
protocol to obtain blood from volunteers. Aliquots of peripheral blood were procured
and stored in 60mL heparin-treated syringes. Mononuclear cells were isolated from the
peripheral blood of healthy donors by Ficoll-Paque density gradient centrifugation. The
peripheral blood mononuclear cells (PMBC) were re-suspended in RPMI 1640 medium
(Gibco) and separated into three experimental groups: 1) Day 0, 2) PBMC Day 1, 3)
Plate-passed Day 1. The “Day 0” experimental group denotes 20 x 106 cells that are
separated and stained on the day of peripheral blood collection. “Plate-passed Day 1”
indicates the 80 x 106 cells that are re-suspended in 8mL RPMI 1640 and passed through
the Glycotech plate apparatus (set-up and illustration below). Following one-way plate
passage, these cells are resuspended in RPMI 1640 supplemented with 15% AB serum
and cultured for 20 hours in 6-well polystyrene tissue-culture plates at a density of 106
cells/mL. To generate cells for comparative phenotypic analysis (“PBMC Day 1), 60 x
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106 cells are re-suspended in RPMI 1640, allowed to sit in the incubator to simulate
temperature conditions for the Plate-Passed experimental group, cultured for 20 hours
similar to conditions described above and collected for FACS analysis.

Glycotech Plate Chamber
Previous research performed by our group had demonstrated that human monocytes
could be efficiently converted to dendritic antigen presenting cells by passage over a
platelet-coated plastic surface. This is in contrast to conventional methods of in vitro
monocyte-to-DC conversion, which requires the addition of exogenous growth factors.
Briefly, a polystyrene surface is coated with autologous platelet-rich plasma and allowed
to form an immobilized platelet layer. A Glycotech flow chamber is placed on top of this
surface and vacuum-sealed, and 4ml of RPMI 1640 is passed through at 1 ml/min and
discarded during the wash step. PMBC (“Plate-Passed” experimental condition) is
passed through the chamber at 0.8 ml/min to allow for ample interaction time between
monocytes and the platelet coating. Subsequently, 40 ml RPMI is passed through the
chamber at 8 ml/min to create high velocity flow to remove any adherent monocytes.
The total 48 ml collected during PBMC plate passage and high-velocity wash phases is
combined and cultured for 20 hours and harvested for phenotyping analysis using multiparametric flow cytometry (Figure 1).
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Figure 1. Diagram of experimental setup using the Glycotech flow chamber.
Peripheral blood monocytes are passed over a platelet-coated polystyrene surface under
vacuum seal under specific experimental conditions: PBMC is passed through the
chamber at 0.8 ml/min followed by flushing of the chamber with 40ml RPMI at 8
min/ml. All volume after passage is collected for overnight culture. *Graphic depiction
courtesy of David Khalil, Yale Department of Dermatology.

FACS analysis
All three experimental groups were analyzed by flow cytometry. In all samples, cells
were also paired with matching isotype controls. Monoclonal antibodies specific for
monocytes and DC maturation included: CD14 (lipopolysaccharide receptor, monocytes);
HLA-DR (human leukocyte antigen DR; class II major histocompatibility complex
[MHC] molecule); CD83 (DC marker); and CD80 and CD86 (B7.1 and B7.2 costimulatory molecules). Cells were blocked with 1:100 normal mouse IgG in 5% AB
serum for 15 minutes then incubated with selected antibodies targeting prioritized surface
molecules for 30min at 4°C (Table 1). Anti-CATB and anti-Neu1 rabbit polyclonal
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antibodies required wash and incubation with FITC-conjugated donkey anti-rabbit
antibody for an additional 30 min at 4°C. Cells were then washed three times and fixed
in 2% paraformaldehyde. To determine the ability of plate passage to induce DC
maturation markers, cells were incubated with PE-conjugated anti-CD83, -CD86, FITCconjugated anti-HLA-DR, -CD80, PCP-conjugated anti-CD11c and APC-conjugated
anti-CD14. All flow cytometric data were analyzed using FlowJo software (Tree Star).
Monocyte-derived DC populations are identified as CD11c+ cells with appropriate
forward and side scatter.

Table 1. Selected antibodies targeting prioritized surface molecules.
Name

Manufacturer

Catalog #

CTSB (rabbit pAb)

Abgent (San Diego, CA)

AP7367c

CXCL16 (anti-human APC-conj. mAb)

R&D Systems (Minneapolis, MN)

FAB976A

ICAM1 (anti-human PE-conj. mAb)

eBioscience (San Diego, CA)

12-0549

MSR1 (anti-human PE-conj. mAb)

R&D Systems (Minneapolis, MN)

FAB2708P

Neu1 (Rabbit pAb)

Abgent (San Diego, CA)

AP9697c

OLR1 (anti-human PE-conj. mAb)

R&D Systems (Minneapolis, MN)

FAB1798P

PLAUR (anti-human APC-conj. mAb)

eBioscience (San Diego, CA)

17-3879

PMP22 (anti-human DyLight 288-conj. mAb)

Novus Biologicals (Littleton, CO)

NB110-59086G

SIPRα (anti-human APC-conj. mAb)

eBioscience (San Diego, CA)

17-1729

TNFRSF1A (anti-human PE-conj. mAb)

R&D Systems (Minneapolis, MN)

FAB225P

TNFSF14 (anti-human PE-conj. mAb)

BD Pharmigen (San Diego, CA)

559446
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In silica identification of upregulated transcription factors after ECP induction
Using the previously delineated list of 466 upregulated genes from the ECP-induced DC
transcriptome, transcription factor genes were identified using the TFCat
(http://www.tfcat.ca/index.php) database.

RNA isolation and gene expression analysis
Peripheral blood monocytes from a single donor were separated into three subsets:
Sample A = monocytes cultured overnight following passage over plate coated with low
density of platelets; Sample B = monocytes cultured overnight following passage over
plate coated with high density of platelets; Sample C = monocytes cultured overnight
without plate-passage. Total RNA was isolated from each subset using the RNeasy
MicroKit (Qiagen, Valencia, CA). cDNA was then prepared from three samples of RNA
using ABI High Capacity cDNA Reverse Transcription kit with RNase Inhibitor (ABI,
Foster City, CA). Amplification of cDNA was achieved using TaqMan Pre-Amp
Mastermix and TaqMan assays specific to the eight transcription factors, all according to
manufacturer’s protocol. Real-Time PCR was performed using TaqMan Gene
Expression Master Mix with TaqMan assays. Ct values obtained were normalized
against housekeeping gene HPRT1 and ΔCT calculated using Sample C as baseline. The
expression difference between conditions was calculated using RQ = 2-ΔΔCT. Monocyte
processing done by Tyler Durrazzo (YMS Class of 2010); RNA isolation performed by
Renata Filler; RNA expression analysis performed by Kristina Liu under the guidance of
Renata Filler.
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IV. Results

In silica analysis identifies 66 upregulated transmembrane genes after ECP induction

Comparison of the database of 466 upregulated genes identified via RNA array against
the list of 1950 full-length human transmembrane genes with immunologic and
hematopoietic cell surface expression yielded 87 genes in common. Further comparison
against five expression profiles of human monocyte derived DCs grown in culture with
GMCSF and IL-4 yielded 66 genes unique to ECP induction. Assessment of gene
function, known relationship to immunologic pathways, and the comparison of raw
transcriptome data prioritized 12 candidate genes for initial testing (Table 2).
Table 2. ECP-enhanced expression of cell surface/transmembrane genes. The 12
genes tested during the first round of experiments are shown in bold.
ABCA1

ENG

KCTD11

OLR1

SC5DL

STX6

ACVR1B

FLOT1

LAMP2

OMG

SEMA6B

TM9SF1

ATP6V0B

GNA15

LEPROT

PI4K2A

SIRPA

TMBIM1

BASP1

GPR137B

MARCKSL1

PLAUR

SLC1A4

TMEM33

BEST1

GPR157

MCOLN1

PMP22

SLC22A4

TNFRSF10B

CPM

HEXB

MFAP3

PVRL2

SLC31A1

TNFRSF11A

CRK

HOMER3

MGAT4B

RAB13

SLC35E3

TNFRSF1A

CSF2RA

ICAM1

MR1

RAB8B

SLC39A6

TNFRSF1B

CTNND1

IRAK1

MRAS

RAB9A

SLC6A6

TNFSF14

CTSB

ITGA5

MSR1

RALA

SLC6A8

TNFSF9

CXCL16

ITGB8

NEU1

RNASE1

STX3

YKT6
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Plate passage induces dendritic cell phenotype in normal subjects

We confirmed findings from previous investigations that plate-passage can induce a
dendritic cell phenotype on processed monocytes from normal subjects 34. We analyzed
the co-expression of CD83 (a marker of early DC maturation) and HLA-DR (highly
expressed in DCs) to assess for evidence of a monocyte to DC transition in six normal
subjects. The peripheral blood from these subjects was processed through the Glycotech
chamber as a laboratory model of the ECP exposure plate. Twelve separate analyses of
peripheral blood samples were run (two blood draws per normal subject on separate
dates).

We observed large increases in the percentage of monocytes co-expressing CD83 and
HLA-DR in both plate-passed and overnight cultured monocytes (Figure 1A). While
overnight culture alone produced an increase of 12.8% in co-expression of these two
surface markers, plate-passage in addition to overnight culture resulted in an additional
5.2% increase in expression. As shown in Figure 2, the last set of bars indicate the mean
± SD for all 11 blood draws (patient n=6), revealing significant enhancement in
CD83/HLA-DR co-expression between plate-passed and overnight culture conditions
(p<0.01) and the plate-passed and overnight culture versus day 0 conditions (p<0.0001
for both comparisons). Of note, the repeat blood draw from Subject 5 yielded very
different results from the rest of the cohort such that it was deemed an outlier and not
incorporated into statistical calculation. The membrane expression of the co-stimulatory
molecules CD80 and CD86 were increased after both overnight culture and plate	
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passage, as demonstrated by representative flow cytograms; however differences in the
expression of these markers did not differ dramatically between overnight culture and
plate-passage (Figure 2A). As expected with monocyte to DC transition, surface
expression of CD14 is decreased in both plate-passed and overnight culture conditions
(Figure 2B). These results confirm previous analyses performed by our laboratory
demonstrating that monocytes can be induced to enter the DC differentiation pathway
after both overnight culture and plate-passage. More significantly, plate passage is able
to induce greater expression of DC maturation markers than overnight culture alone.

Figure 2. The percentage of monocytes induced to become leukocytes with DC
phenotype as analyzed by the percentage of cells co-expressing CD83 and HLA-DR.
The three experimental conditions indicate: D0= fresh PBMC; Overnight culture =
cultured overnight in media without cytokines; Plate = passage through the Glycotech
chamber and cultured overnight without cytokines. Dual-color flow cytometry analysis
was performed on each experimental condition from 11 blood draws using 6 healthy
donors. Monocyte population was gated on CD11c+ population and confirmed using
forward and side scatter. Data bars to the right of graph are the mean ± SD. *, P < 0.01,
compared with D0; **, P < 0.01, compared with Overnight Culture.
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Figure 3. (A) Increase in co-expression of CD80 and CD86 on monocytes after
overnight culture and plate-passage. Representative flow cytograms from 3 donors
showing markers of maturation at three experimental conditions: D0= fresh PBMC;
Overnight culture = culture overnight in media without cytokines; Plate = passage
through the Glycotech chamber and cultured overnight without cytokines. Donor 1 is
represented in the top 3 graphs, Donor 2 is represented in the middle graphs and Donor 4
is represented in the bottom graphs. Donors 3, 5, and 6 had similar trends of costimulatory marker expression (data not shown). Two-color membrane staining using
CD80 (FITC) and CD86 (PE) was performed for the identification of surface expression.
(B) Decrease in surface expression of CD14 after overnight culture and platepassage. Monocytes undergoing the transition to leukocytes with DC phenotype were
further assessed for loss of CD14+ surface expression. The three experimental conditions
are the same as in Figure 2. Change in CD14+ expression calculated as the difference in
mean fluorescent intensity (MFI) between CD14 antibody and isotype control antibody
for each subject and condition. Data bars to the right of the graph indicate mean ± SD. *,
P < 0.01, compared with D0; **, P >0.05, compared with Overnight Culture.
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Induction of selected surface markers in treated monocytes

Monocytes in the plate-passed condition are culture overnight for 18 hours to allow
sufficient time for gene activation, cell maturation and surface marker expression. To
assess whether the observed phenotypic changes are a result of monocyte interaction with
platelets and the plastic plate surface, we cultured a portion of each patient’s monocytes
overnight without plate-passage to eliminate any confounding influences exerted from
overnight culture alone. Baseline surface expression is established by staining PBMC on
the day of sample collection. Expression of the 12 selected surface markers was assessed
using flow cytometry. The monocyte population was gated using forward and side
scatter and confirmed by CD11c staining. A representative flow cytometry histogram of
one of the healthy subjects tested is shown in Figure 4 to demonstrate the use of ΔMFI
(mean fluorescent intensity) to calculate increases in expression across experimental
conditions.
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Figure 4. Representative flow cytometric histogram comparing a normal subject’s
monocyte population at Day 0, after overnight culture, and after plate-passage.
Numbers in blue and red denote units of fluorescent intensity for isotype control (APCIgG1) and PLAUR antibody (APC-PLAUR). ΔMFI = MFI of candidate antibody (red) –
MFI of isotype control antibody (blue). Monocyte population gated on CD11c+
population and confirmed using forward and side scatter. 2.67 fold and 6.55 fold
increases in expression are seen after overnight culture and plate passage, respectively, as
compared to fresh PBMC.

This typical flow cytometric histogram of a normal subject’s monocyte population
reveals marked increases in expression after overnight culture and plate passage. This is
mostly to demonstrate the way we calculated change in expression using ΔMFI
(subtraction of background isotype control fluorescence from fluorescent intensity of
antibody staining). Here we see significant increases in ΔMFI after both overnight
culture and plate passage, and more interestingly, an increase from overnight culture to
plate passed.
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Twelve selected genes were tested using the three experimental conditions stated above.
Statistically significant changes in expression after plate-passage was identified in five
genes: ICAM1, PLAUR, TNFR1, CXCL16 and SIRPa. Three of these five genes,
ICAM1, PLAUR and TNFR1, further demonstrated significant differences in expression
between the plate-passed and overnight culture conditions. Only one gene, TNFR1, was
found to have down-regulation of expression after both treatment conditions (Figure 5).
These results are consistent with previous findings of a characteristic gene expression
profile induced by ECP treatment. The five highly upregulated genes possess a variety of
functions associated with DC adhesion, proliferation and function, further supporting the
need for more focused, individual gene analyses (Table 2).
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Figure 5. Surface markers with differential expression after plate-passage.
Calculation of ΔMFI was performed for the twelve candidate genes across 11 separate
trials. Five genes demonstrated significant changes in expression after plate-passage as
compared to fresh PBMC. Two genes showed significantly increased expression after
plate-passage as compared to overnight culture. Statistical analyses were performed
using two-tailed, student’s t-test. Significant p-values (p < 0.05) are identified in black;
p-values > 0.05 are labeled in green.
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Table 3. Candidate genes with statistically significant increases in cell surface
expression after plate-passage.
Genes

Attributes

CXC chemokine ligand

Receptor for CXCR6 expressed on activated T cells; attracts effector and

16 (CXCL16)

cytotoxic T cells

Signal-regulatory

Negative regulator of tyrosine kinase-coupled signaling pathways;

protein alpha (SIRPα)

overexpression inhibits tumor transformation and enhance tumor apoptosis

Tumor necrosis family

Though TNF signaling, mediates immunogenic and immunomodulatory

receptor 1 (TNFR1)

functions; major roles in DC maturation, T cell priming, proliferation and
recruitment

Intercellular adhesion

Interacts with LFA1, responsible for cell adhesion, rolling and migration

molecule 1 (ICAM1)
Plasminogen activator,

Urokinase receptor involved in degradation of extracellular matrix proteins,

urokinase receptor

chemotaxis, and adhesion via binding to integrins; crucial in the recruitment

(PLAUR)

of T cells

Increased expression of 7 transcription factors distinguish ECP-treated monocytederived DCs

To identify transcription factors (TFs) expressed by ECP-treated monocyte-derived DCs
but not in untreated peripheral blood monocytes, we began by performing an in silica
analysis of the RNA array data from Berger et al.34 TFs were identified using crosscomparison against the TFCat (http://www.tfcat.ca/index.php) database and further
selected for DC-specific gene expression and roles in immunity through extensive

	
   25	
  

	
  
literature searches. Eight candidate TFs were selected for expression comparisons by
RT-PCR.

Table 3. TF genes with upregulated expression on RNA array.

Genes

Attributes

B-cell leukemia/lymphoma 3 (BCL3)

Expressed in bone marrow-derived DCs, substantial role in
immune regulation; proto-oncogene candidate, identified
in some cases of B-cell leukemia41,42

Broad complex, Tramtrack, Bric-à-brac,

Function largely uncharacterized; activates promoter of

and Zinc finger family 3 (BTBD3)

CD56, which is involved in proliferation and antiapoptosis43

Broad complex, Tramtrack, Bric-à-brac,

Selectively expressed by classical DCs (cDCs) and their

and Zinc finger family 4 (BTBD4)

committed progenitors37

cAMP responsive element modulator

Possible DC maturation marker44,45; involved in multiple

(CREM)

intracellular signaling cascades46

Cyclin-dependent kinase inhibitor 1A

Expression tightly controlled by p53, mediates G1 cell

(CDKN1A)

cycle arrest; Crucial for differentiation of peripheral blood
monocyte precursors to functional DCs47,48

Growth arrest and DNA-damage-

Expression increases following stressful growth arrest;

inducible 45 alpha (GADD45A)

mediates activation of p38/JNK pathway; expressed in late
maturation of DC49,50

Nuclear factor of kappa light

One study shows NFkB2 to be requisite for DC cross-

polypeptide gene enhancer in B-cells 2

presentation; another shows decreased NFkB2 activity

(NFKB2)

enhances DCs’ ability to induce CD4+ T cell response51,52

Vitamin D receptor (VDR)

Nuclear hormone receptor; assists DCs in sensing their
lipid environment and modulating the immune response53
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To assess the effect of ECP treatment on TF expression, and to compare the impact of
passage through a plate coated with varying densities of platelets, three sets of RNA
samples were analyzed: Sample A= monocytes treated with a model-ECP plate coated
with low density platelets, then cultured overnight; Sample B = monocytes treated with a
model-ECP plate coated with high density platelets, then cultured overnight; and Sample
C = monocytes cultured overnight without treatment. The samples were run in triplet and
the relative quantitation, or RQ, was calculated54. The RQ demonstrates the fold change
in expression of mRNA sequences in the treatment samples, Sample A and Sample B,
relative to the same sequence in the control sample, Sample C.

With the exception of GADD45A, which demonstrated essentially unchanged expression
compared to the control (RQ = 1.02 and 1.03 for low- and high-density platelets,
respectively), mRNA expression was increased for all seven TFs after passage through
the model-ECP plate with high density platelets (Figure 6). Increased platelet density
induced directional changes in expression (ΔRQ > 0.5) for VDR, NFkB2, CDKN1A and
BCL3. BTBD4, a transcription factor recently identified as being specifically expressed
in cDCs,37 demonstrated ~3 fold increases in expression after treatment (RQ = 2.89 and
3.14 for low- and high-density platelets, respectively). CREM, an important component
of cAMP-mediated signal transduction and possible DC maturation marker, was
significantly upregulated with both platelet treatments (RQ = 6.78 and 5.9 for low- and
high-density platelets, respectively).
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Figure 6. Seven transcription factor mRNA levels show increased expression in
plate-passed monocyte-derived DCs vs. untreated monocytes. Sample A (blue)
denotes plate-passage over a low-density platelet bed; Sample B (red) denotes platepassage over a high-density platelet bed. Calculation of relative quantitation (RQ)
performed via comparison to the control condition (untreated monocytes). Seven of the
eight TFs demonstrated increased mRNA expression after plate-passage over highdensity platelet beds. Increased platelet density induced directional changes in the
expression of four TFs (ΔRQ > 0.5).
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IV. Discussion

Tremendous progress in DC research has been made in the past twenty years, starting
with the development of a simple method for generating DCs from peripheral blood
monocytes.55 This method of culturing monocytes for three to six days in the presence of
GMCSF and IL-4 results in populations of immature dendritic cells, which can be further
induced to mature with the addition of stimulatory cytokines to the media. Results from
studies by Berger et al. demonstrating the conversion of blood monocytes from CTCL
patients into cells with DC phenotype raised the possibility that functional dendritic cells
can be produced on a large scale without the addition of exogenous cytokines.34
Conceivably, DCs produced through this method would better mimic physiologic
signaling. By seeking to define and characterize ECP-induced monocyte-derived DCs
using surface markers and unique patterns of TF expression, these cells may one day be
preferentially induced to assume immunogenic or immunosuppressive states and used to
tailor ECP to the treatment of specific conditions.

The results of this study provided evidence for a phenotypic, monocyte to DC transition
after plate-passage, and extended results from our laboratory’s previous findings to
validate the use of the bench-top Glycotech flow chamber as an appropriate model for the
significantly larger ECP UV-exposure plate. We demonstrated that plate-passage is
critical for the induction of DC phenotype as monocytes cultured overnight produced
significantly less differentiated leukocytes with lower surface co-expression of CD83 and
HLA-DR, and higher surface expression of CD14. Two of the twelve candidate genes
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also required passage through the plate for high levels of gene activation as overnight
culture induced comparably lower levels of expression. Our laboratory is currently
exploring the relationship of monocyte-to-platelet interactions as a major factor in ECPinduced monocyte activation. To assess whether the density of the adherent platelet bed
alters monocyte gene activation, quantitative analysis of TF expression was performed
using Glycotech chambers with low- and high-density platelet beds. Four of eight TFs
(50%) assessed demonstrated directional changes in expression with platelet density, and
seven of eight TFs (87.5%) were found to have increased expression after plate-passage
over the high platelet bed. These findings further support our original hypothesis that
plate-passage, as a model for the ECP apparatus, rapidly produces large numbers of
monocyte-derived DCs under more physiologic environments than what previous culture
methods allowed, and these cells possess a very distinct expression pattern that will
enable its delineation, both in phenotype and function, from other DC subsets.

The five cell surface markers that demonstrated increased expression after plate-passage
merit further exploration for their potential roles in DC biology or DC-T cell interaction.
These molecules, as briefly discussed in Table 2, all possess interesting DC or
immunologically related functions. For example, CXCL16, or CXC chemokine ligand
16, is a transmembrane chemokine actively transcribed by myeloid DCs to attract effector
cells with its corresponding receptor, CXCR6.56,57 It has the unique function of being
both an endocytic receptor as well as the only known ligand of CXCR6 (CXC chemokine
receptor 6) expressed on activated T cells.58,59 Furthermore, CXCR6 expression on
central memory T cells becomes significantly upregulated after interaction with mature
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DCs expressing CXCL16, suggesting that this interaction is important in supplementing
the effector memory T cell response in states of infection and inflammation.59 CXCL16
appears to be one of the initially produced chemokines in the setting of viral infections to
attract effectors and cytotoxic T cells to provide a timely response to curb the infection.60
It also acts as an inflammatory cytokine in the setting of bacterial infections via
regulation of IFN-ɣ and cell-mediated immunity.58,61,62 In addition, membrane-bound
CXCL16 plays important roles in antigen presentation, such as facilitating bacterial
phagocytosis by professional APCs such as dendritic cells.62 Thus, increased CXCL16
expression after treatment with plate-passage may indicate enhanced aptitude of these
monocyte-derived DCs in the uptake of various pathogens and antigens as well as
attracting T and Natural Killer T (NKT) cells.56

SIRPα, or signal-regulatory protein alpha, is a transmembrane glycoprotein and negative
regulator of receptor tyrosine kinase-coupled signaling pathways.63 It is expressed
predominantly on monocytes, DCs and their precursors. In 1999, Seiffert et al. identified
the ligand for human SIRP as CD47, a broadly-expressed plasma membrane protein with
myriad cellular functions.64 CD47 is associated with αⅴβ3 integrins and regulates integrin
function; in the hematopoietic system, this is limited to megakaryocytes and platelets.65
Evidence has also shown that CD47 is involved in adhesion to vitronectin,
transendothelial migration and costimulation of T-cell activation66,67. Ligation of SIRPα
with a binding antibody leads to the inhibition of many leukocyte functions such as
phagocytosis, transmigration and TNF production.68 In monocytes, SIRPα acts as a
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negative regulator of adhesion and recruitment during inflammation, as mediated by β2
integrins. This is suggestive of SIRPα’s role in reducing the migration and attachment of
monocytes and other leukocytes in the setting of inflammation.68,69 Using glioblastoma
cells as an in vitro tumor model, overexpression of SIRPα1 led to inhibition of
transformation and enhanced apoptosis following tumor irradiation, as well as reduced
tumor cell migration. These findings were thought to result from negative regulation of
EGFR-induced PI3-K pathway activation.70 Thus it may be worth examining the
presence of CD47 expression on CTCL cells and their interaction with plate-passed
monocyte-derived DCs with enhanced SIRPα expression.

The next upregulated candidate gene, TNFR1, is especially reflective of the multi-faceted
nature of ECP. TNFR1, or tumor necrosis family receptor 1, belongs to a well-known
family of ligands and receptors that play important roles in inflammation and
autoimmunity. Using animal models with dysregulated TNF expression, it has been
shown that the TNF/TNFR system possesses immunogenic and pro-inflammatory as well
as immunomodulatory and disease-suppressive functions.71 This is supported by the
evidence of TNF-α and its receptors’ pleiotropic roles in DC maturation, T cell priming
and proliferation, and T cell recruitment and function.72-76 While some studies have
shown that TNF-α is essential for T cell activation, others report that TNF-α and TNF
receptors can actually suppress T cell immunity. This discrepancy is thought to be a
result of the differential timing of TNF-α release during the immune response.77-81 TNFα blocking agents have been used clinically with success in several inflammatory and
autoimmune conditions without thorough understanding of the exact molecular level at
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which TNF-α inhibitors are interfering with pathogenesis. The results observed in our
study showing down-regulation of TNFR1 expression after plate-passage is interesting,
and may indicate that these newly produced monocyte-derived DCs are maintained in a
fairly immature state, or may be reflective of a finding that is unique to the processing of
monocytes from healthy subjects. The combination of plate-passage without a preexisting antigen to initiate or sustain an immune response may decrease the relevance of
TNF-α signaling and result in the down-regulation of its receptors. Further analysis of
TNFR1 expression on monocytes isolated from patients with CTCL and GVHD should
be performed.

ICAM1, or intercellular adhesion molecule 1, belongs to a class of well-studied cell
adhesion molecules belonging to the immunoglobulin superfamily.82 ICAM1 interacts
with its ligand LFA1 (lymphocyte function associated antigen 1), and this pairing is
integral to many aspects of normal immune function, including immune cell migration
and response. Members of the CAM (cellular adhesion molecule) family are responsible
for the adhesion, rolling and migration of numerous cellular subsets, including
monocytes, eosinophils, memory T cells and neutrophils.83 Furthermore, immunogenic
stimuli, such as TNF-α, lead to increase cell surface expression of ICAM1, facilitating
the recruitment of leukocytes to sites of inflammation.84 Looking specifically at ICAM1
expression in monocytes and monocyte-derived dendritic cells (cultured in GMCSF/IL4), studies reflect either slight down-regulation or constant expression suggestive of
relative non-importance in monocyte to DC differentiation.50,85 The significant increase
in expression seen in our plate-passed monocyte-derived DCs as compared to simple
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overnight culture suggest an element of plate-specific stimulation of these monocytes that
may allow them to more effectively engage, for example, naïve CD8+ T cells and induce
their activation and differentiation into potent cytotoxic T cells.86 It will be important to
confirm published results of ICAM1 expression on classical DCs in the same
experimental context as our plate-passed monocyte-derived DCs.

PLAUR (plasminogen activator, urokinase receptor), or CD87, is an intriguing molecule
involved in adhesion, proteolysis and chemotaxis. When its ligand, urokinase (uPA)
binds to PLAUR, plasminogen is converted to proteolytically active plasmin and
facilitates extracellular matrix protein degradation.87 This enzymatic activity allows
monocytes and dendritic cells to penetrate collagen barriers during cell-directed
migration to the periphery or lymph nodes.88 In addition, PLAUR can bind vitronectin,
an integrin ligand, as well as other integrins at vitronectin-independent sites.87 It also
possesses domains with chemotactic activity; in fact, PLAUR has been found to be
requisite for monocyte chemotaxis in in vitro experiments using blocking antibodies and
antisense oligonucleotides.89 Studies have shown that both immature and mature
monocyte-derived dendritic cells express low levels of PLAUR.55,90 The relevance of
PLAUR and uPA in the generation of appropriate immune responses has been tested
using homologous recombinant mice lacking uPA. These animals exhibit an
immunodeficient phenotype resulting from inadequate recruitment of T cells, and
ultimately succumb to uncontrolled infection.89 In a study examining the role of CD87 in
the activation of T cells by DCs, monocyte-derived DCs (after culture with GMCSF and
IL-4) were tested in proliferation assays and mixed lymphocyte reaction assays with
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CD87-blocking monoclonal antibodies. These antibodies were able to inhibit autologous
T cell proliferation as well as block the activation of naïve and memory T cells,
highlighting the important role of PLAUR in immune induction.91 The significant
increase in the expression of PLAUR on plate-passed monocyte-derived DCs as
compared to DCs after overnight culture may indicate plate-passage associated
enhancement in cell-directed migration as well as T cell stimulation. These five cell
surface molecules, along with other candidates in the testing pipeline, will serve to define
and characterize this unique subset of ECP-induced monocyte-derived DCs that represent
a more physiologic model of DCs in vivo.

To complement the search for ECP-induced monocyte-derived DCs surface markers, we
extended our in silica analysis to transcription factors. Identification of populationspecific TFs would expand and confirm categorization based on patterns of surface
marker expression. Using gene expression analysis to identify TFs expressed in ECPinduced monocyte-derived DCs, we identified seven TFs with increased expression in
monocytes after plate-passage (over platelet beds with high and low density). Using gene
expression analysis to identify TFs expressed in ECP-induced monocyte-derived DCs, we
identified seven TFs with increased expression in monocytes after plate-passage over
high-density platelet beds. BTBD4, a recently identified TF specifically expressed by
cDCs, was found to have significantly increased expression after plate-passage.39 While
the functional role of BTBD4 is yet undetermined, it would be interesting to explore in an
animal model, such as the BTBD4 knockout mice, how these cDCs function in the setting
of immune challenge, or to assess the role of BTBD4 using functional assays in both
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ECP-induced and GMCSF/IL-4 cultured DCs. Four TFs (VDR, NFkB2, CDKN1A and
BCL3) demonstrated directional changes in expression with increased platelet bed
density, suggestive of possible monocyte-platelet interactions that altered gene expression
activation. VDR, or vitamin D receptor, is a nuclear hormone receptor shown to play a
role in the differentiation and function of monocyte-derived DCs.92 The ligand of VDR,
1,25(OH)2D3 (calcitriol), is the active form of vitamin D, and is essential for the
regulation of serum calcium and phosphate to maintain normal bone mineralization.
Surprisingly, VDR is not just expressed in the gut or musculoskeletal system; instead it is
expressed in essentially every tissue in the human body, thereby making vitamin D a key
player in many conditions such as autoimmune disease, infections and cancers.93
Vitamin D exerts its effect through the binding of nuclear VDR, which regulates
downstream gene expression via many molecular pathways.94 Studies looking at the
direct effect of calcitriol on monocytes and DCs have shown that it plays an essential role
in DC differentiation and immunostimulatory capacity, through regulation of several
genes with immune functions, particularly genes that make up a tolerogenic DC
phenotype.95 Calcitriol treated DCs are especially adept at inducing CD4+CD25+ Tregs
to limit the inflammatory response.96-98 It would be informative to see whether
expression of VDR is similarly enhanced with the plate-passage of monocytes from
CTCL and GVHD patients, and whether the upregulation of such an
“immunosuppressive” TF is dependent on the internal milieu from which the monocytes
are derived.

Recently, the noncanonical NFkB pathway has been implicated in controlling the
	
   36	
  

	
  
immunoregulatory phenotypes in both classical and plasmacytoid DCs.99 The
noncanonical NFkB pathway refers to a pathway that involves the induction of NFkBinducing kinase (NIK) and its downstream signaling events. Activation of this pathway
involves signaling through TNFR family members, such as CD40. In a study specifically
assessing the role of NFkB2 in DC function, NFkB2 was found to be crucial in DC
function such as the cross-priming of CD8+ T cells.51 In a separate study looking at
RelB, another member of the NFkB family, it was found that RelB is regulated by
cytoplasmic NFkB2, which serves as a negative regulator of DC’s ability to express costimulatory molecules and induce CD4+ T cell responses.52 Given the complexity of
NFkB2 signaling and its myriad of downstream effects in DC maturation and function, it
will be important to assess the functional competency of plate-passed monocyte-derived
DCs against GMCSF/IL-4 cultured DCs and their NFkB2 expression to further explore
the aforementioned findings.

CDKN1a, a cyclin-dependent kinase inhibitor, is another TF whose expression was
significantly elevated after plate-passage. Kramer et al. identified the obligate role of
CDKN1a induction in monocyte differentiation. Monocytes induced to enter the DC
differentiation pathway under GMCSF/IL-4 culture conditions were treated with
CDKN1a antisense nucleotides, which blocked their phenotypic differentiation and
ability to stimulate T cells.47 Furthermore, gene microarray data performed on DC
exposed to T cells treated with immunostimulatory cryotreatment demonstrated
upregulation of CDKN1a along with other genes involved in DC maturation, such as
IL1β and Fas.100 BCL3 is a well-studied oncogene for hematopoietic malignancies such
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as B cell chronic lymphocytic leukemias, although not much is known about its
relationship to dendritic cell immunobiology. Last but not least, CREM, a cAMP
responsive element modulator, demonstrated the highest fold change in expression after
plate-passage compared to untreated monocytes. Reports in recent literature has found
CREM to be a possible marker of monocyte-derived DC activation.44,45,101 A comparison
of CDKN1a, BCL3 and CREM expression on ECP-induced monocyte-derived DCs to
GMCSF/IL-4 cultured DCs will shed further light on the impact of plate-passage on
monocyte differentiation. Figure 7 highlights the pertinent surface markers and
transcription factors as they contribute to the process of monocyte-to-dendritic-cell
differentiation.

Passage&through&ECP&plate&
↓TNFR1&–&maintenance&
of&DC&immaturity&
↑ICAM1&–&eﬀec<ve&
engagement&&&
ac<va<on&of&T&cells&
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VDR&–&key&role&in&
moDC&diﬀeren<a<on&
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Figure 7. Summary of the postulated roles of surface markers and transcription
factors involved in development of monocyte-derived dendritic cells. DC = dendritic
cell. moDC = monocyte-derived dendritic cell.
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A study conducted by Woodhead et al. in 2000 demonstrated that PLAUR plays a
functional role in DC activation of T cells using GMCSF/IL-4 cultured DCs.91 This
highlights the importance of assessing the functional competence of ECP-induced DCs in
the context of each of our candidate genes, many of which have available blocking
antibodies. To determine if plate-passed monocyte-derived DCs are capable of
stimulating normal T cell responses to MHC Class I and II antigens or mediating
cytotoxicity by targeting HLA on specific lymphocytes, we can employ antigen
presenting assays or mix lymphocyte reaction assays. Another major objective is to
expand the number of subjects assessed to confirm the universal presence of our
candidate genes, as well as look for gene expression in the peripheral blood of patients
with CTCL, to assess how a diseased internal milieu or treatment with the actual ECP
apparatus alters candidate gene expression. We are continuing to identify additional
surface markers from the list of 66 candidate genes using the same methodology
described above. Ultimately, we hope these surface markers and TFs will serve to better
define and characterize this unique population of ECP-induced monocyte-derived DCs.
On a more global scale, this project fits nicely into a larger endeavor to better understand
the efficacy of the ECP apparatus, likely mediated in large part through dendritic cells,
and have significant implications in defining a process of developing more physiologic
DCs for other branches of research.
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Appendix A: DNA Copy-Number Analysis of Selected Genes in Patients with CTCL

I.

Introduction

Copy-number variations (CNVs) are extensive genomic structural variations that range in
size from kilobases to megabases. CNVs can result from deletions, duplications,
inversions and translocations, which can lead to deletion of a gene or acquisition of
additional copies of a gene. Early studies of genetic alterations in CTCL identified
candidate regions containing DNA copy-number variations, some of which potentially
correlate with disease progression and prognosis.102 Previously, a high-resolution
genomic analysis and meta-analysis of patients with leukemic CTCL performed in our
laboratory has defined regions of significant copy-number variation to help discern some
of the common DNA copy-number alterations characteristic of CTCL.103 These regions
of copy-number variation can contain a high number of genes; for example, chromosome
17q contains over 300 genes. This current study focuses on select regions of
amplification to assess copy-number amplification on a gene-specific level.

II. Statement of Purpose
To validate gene specific copy number amplifications and assess whether these
changes occur consistently across a sample population of CTCL patients, with the
goal of finding genetic alterations that play a role in pathogenesis.
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III. Methods
The top six regions of amplification based on the highest frequency and magnitude of
gain from our previously published genomic analysis were selected (Table A1).103
Within these regions of interest, 381 genes were prioritized using five selection criteria
(Figure A1). From this list, six genes fulfilled four of the five selection criteria and
twenty-one genes fulfilled three of the five selection criteria. These 27 genes were then
further filtered for the availability of targeted therapy to comprise the final list of ten
genes: STAT3, BECN1, SKAP1, NGFR, TAC4, PRKAR1a, HN1, GRB2, SPHK1 and
UBR4.
Table A1. Significant regions of DNA copy-number amplification described by
Lin et al. (JID 2011).
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Figure A1. Gene selection workflow used in the prioritization of candidate genes for
copy-number analysis.

Copy number alterations occurring in these ten genes were assessed by quantitative PCR
(TaqMan Copy Number Assays, Applied Biosystems) using DNA prepared from purified
malignant T cells from 14 patients. Two sets of controls were used for comparison:
pooled DNA from CD4+ T cells of healthy volunteers and purchased pooled human
DNA (Promega, Fitchburg, WI). Six genes showing copy number amplification were
further tested using DNA from 5 CTCL and 1 T-cell lymphoma cell line.

IV. Results
As Figure A2 shows, copy number amplification for each selected gene is calculated
relative to both sets of controls (N1 = normal volunteers; N2 = Promega pooled human
genomic DNA). For the analysis of SKAP1, the copy number amplification calculated is
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closely matched between the two controls, and 8 of 14 patients were found to have copynumber amplification >2.5 (Figure A2a). Conversely, Figure A2b shows NGFR, which
demonstrated poor correlation between the calculated copy-number amplifications
between the two controls.

Figure A2. Representative graph of CNV in SKAP1 (a), a top-ranking candidate gene,
showing 43% of patients with >3 gene copies. Copy-number amplifications relative to
both controls are comparatively similar. In contrast, there are disparities in copy-number
amplifications relative to controls for NGFR (b). Genes exhibiting such differences in
calculated CN were excluded from further analysis due to inability to ascertain true
number of gene copies.
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Of the ten genes, one gene was excluded from further analysis due to lack of
amplification, three genes were excluded based on lack of correlation between the two
controls used, and six genes were amplified in >30% of patients tested (Table A2). Four
genes (SKAP1, PRKAR1a, GRB2 and STAT3) were then further tested for copy-number
amplifications using DNA from four CTCL and one T cell lymphoma cell lines. STAT3
was amplified in four of the six cell lines. Amplifications of the other three genes were
found in certain cell lines, although the results did not appear gene-specific (Table A3).
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Table A2. Summary of gene copy numbers calculated relative to normal (CN=2.00).
N1 indicates pooled normal controls; N2 indicates purchased Promega normal DNA.
Shaded boxes indicate calculated copy number amplification (CN > 2.5).
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Figure A3. Summary of copy number analysis for five CTCL cell lines (SeAx, Sez4,
Pno, Hut78, MyLa) and one T cell lymphoma cell line (Jurkat). N1 indicates pooled
normal controls; N2 indicates purchased Promega normal DNA. Shaded boxes indicate
calculated copy number amplification (CN >2.5).

V. Discussion
In recent years, significant research effort has been directed toward understanding the
molecular genetic events underlying multiple types of malignancies with the hopes of
improving diagnosis and identifying novel therapeutic targets. Studies utilizing
comparative genomic hybridization and copy number analysis have unearthed a number
of chromosomal abnormalities in CTCL, although with varying results.102,104-109 In this
study, we aimed to build upon previous work performed in our laboratory to validate
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gene-specific copy number amplifications to delineate genetic alternations characteristic
of CTCL.

Six genes within candidate regions of copy-number amplification were identified via our
analysis: SKAP1, PRKAR1a, STAT3, BECN1, GRB2 and HN1. SKAP1, a src kinase
associated phosphoprotein, encodes a T-cell adaptor protein that plays a critical role in
the T cell receptor “inside-out” signaling. SKAP1 complexes with RapL to bind
lymphocyte function-associated antigen 1 (LFA-1), a β2 family integrin, in a pathway
that regulates T cell adhesion, motility and interaction time with antigen presenting
cells.110,111 Furthermore, van Doorn et al. found that SKAP1 resides in a loci of recurrent
gain and demonstrated copy-number amplification associated increases in expression in
MF.112 Another candidate gene, PRKAR1a, is a cAMP-dependent protein kinase
regulatory subunit shown to be amplified and overexpressed in analyses by Lin et. al and
Caprini et. al.103,106 As discussed in Lin et. al, overexpression of PRKAR1a has been
found to induce increased expression of IL-2; indeed, it is possible PRKAR1a
amplification may result in IL-2 pathway activation, thereby enhancing the proliferation
of malignant T cells through the up-regulation of JAK/STAT, P3K/AKT and mitogenactivated protein kinase pathways.103,113,114 It is also noteworthy that STAT3, also
involved in the IL-2 signaling pathway and whose constitutive activation has been
implicated in Sézary syndrome, is another highly prioritized candidate gene.115-117

Several genes were excluded from further analysis using cell line DNA due to disparities
in copy number calculation based on the two controls employed. This may have resulted
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from differential binding of the chosen primers with purchased versus pooled control
DNA. Due to these large differences in calculated copy number, we were unable to
accurately assess whether true amplification occurred and will defer further testing of
these genes until further analysis. Copy number analysis using CTCL and T cell
lymphoma cell lines demonstrated inconsistent amplification in all genes except STAT3,
a result consistent with previous reports of amplification and differential expression of
STAT3 in Sézary syndrome. Uniform amplification of all six genes was seen in Sez4 and
Hut78 cell lines, possibly indicating more widespread genetic alterations within these cell
lines that are reflective of potential dissimilarities between patient samples and cells
lines, which have undergone multiple passages requiring additional growth factors.

Looking forward, these genes with copy number variations will need confirmation of
gene expression changes using quantitative real-time PCR. If a dosage-effect is seen,
then expression can be inhibited with siRNA technology to assess the genes’ functions in
proliferation or cellular functions of CTCL cells. We have long believed that persistent
changes at the genomic level in cancer cells represent a critical target for the study of
carcinogenesis. We hope to have contributed to this effort through the study of selected
candidate genes in CTCL patients as well as established cell lines, and that this may serve
as part of the platform on which functional validation of copy number variation and
potential therapeutic ventures can launch.
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Appendix B: Identification of Novel Genetic Alterations in CTCL via Whole Exome
Sequencing

Recent advances in genome-wide analyses have significantly increased our understanding
of the genomic landscape behind human diseases, including cutaneous T-cell
lymphoma.105,106,118 The human genome is comprised of ~3 billion nucleotides of DNA;
however, only a small percentage – 1.5 percent – of those nucleotides are actually
translated into proteins that play a functional role in the body. Sequencing of the
“exome” therefore arises as an ideal strategy for the identification of genetic variants that
underlie human disorders since the vast majority of variants that have effect on diseaserelated traits encode protein. Furthermore, the cost of whole exome sequencing remains
significantly less expensive than whole genome sequencing, making this a novel, robust
and cost-effective method for the identification of functional variation responsible for
cutaneous T-cell lymphoma.119-121

We hypothesized that there exist single nucleotide variants within the malignant clone of
CTCL cells that are: 1) associated with pathogenesis, in particular those leading to the
development of malignant or immunosuppressive phenotypes; 2) associated with
prognosis and markers for disease staging; and 3) useful for the identification of potential
novel targets for therapeutic intervention. To test this hypothesis, we selected for
phenotypically similar patients with clinically severe Sézary syndrome. Patients enrolled
include patients actively being treated in the photopheresis unit, past patients of
photopheresis (currently receiving chemotherapy at Smilow Cancer Center) or past
patients whose samples have been frozen down for previous studies conducted in our
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department. Malignant T lymphocytes were enriched from the peripheral blood of these
patients using: 1) Vβ-specific antibody if available, or 2) negative selection with either
CD7 or CD26 antibodies as determined based on phenotypic data. Cell aliquots are
removed during the enrichment process to assess for cell viability, to verify the purity of
the enriched populations, as well as confirm certain phenotypic features of the cell
populations (Figure B1). CD4+ T cells from healthy donors are also isolated via positive
selection using CD4+ magnetic beads for use as the control.

Figure B1. Purification of malignant T cells using negative selection. Peripheral
blood samples of CTCL patients are enriched for the malignant T lymphocyte population
using negative selection with CD7 and CD26 antibodies (as determined by flow
cytometric phenotypic data in this patient). Cell aliquots are removed to assess for
viability using forward and side scatter (data not shown). Compared to the unfractionated
population (a) with 12.4% CD3+CD4+ population, the enriched fraction is 93.5%
CD3+CD4+ (C) as well as >99% CD7-CD26- (b).

Genomic DNA was purified from 18 patients and two healthy donors. Samples of
sufficiently high purity were submitted for whole exome sequencing, and the
identification of variants is currently underway with results available pending
completion.
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Appendix C: Detection of peripheral blood involvement in CTCL by multiparametric flow cytometry analysis

Identification and quantification of Sézary cells can be monitored through analysis of the
peripheral blood, e.g. flow cytometry, including T-cell receptor variable region beta
(TCR-Vβ). At Yale we use multiple T cell markers for the diagnosis and tracking of
disease burden in patients with leukemic CTCL. We sought to explore the utility of a
multi-parametric flow cytometry strategy in the evaluation of tumor burden in CTCL by
conducting a prospective case-series of 13 patients referred to the Yale Photopheresis
Clinic over 18 months. Flow cytometry analysis was performed using multiple TCR
markers, including: CD2, CD3, CD4, CD5, CD7, CD8, CD25, CD26, CD45, CD45RA,
CD45RO (Yale Laboratory Medicine) and TCR-Vβ panel (ARUP Laboratories, Salt
Lake City, UT).

Flow cytometry consistently revealed a phenotypically abnormal T cell population with
altered expression of lymphocyte markers, including CD3, CD4, CD7 and CD26. Nine
of the thirteen patients had loss of CD7, twelve of thirteen patients had loss CD26 and
eight of thirteen patients had alterations in additional markers (Table C1, Figure C1).
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Table C1. T cell markers used at Yale to identify the neoplastic population in
CTCL patients. Patients 1-7 have expanded TCR Vβ found on ARUP panel; patients 813 do not have an identifiable TCR Vβ. Notably, 100% of patients’ neoplastic
populations were CD5+ and CD8- (data not shown). Loss of CD7, a common phenotype
observed in circulating CTCL cells, was only observed in 64% of patients. 93% of
patients had partial or complete loss of CD26. Other significant phenotypic changes
include alterations in CD2, CD3, CD4, CD25 and CD45.
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Figure C1. Initial flow cytometry analysis on Patient 1. All plots shown are derived
from the lymphocyte gate. ~10% of total circulating cells (30% of lymphocytes) are
CD3dim+ CD4dim+ CD8- CD2+ CD5+ CD7+ CD26- T cells, consistent with
involvement of peripheral blood by the patient's known T-cell lymphoproliferative
disease (Flow cytograms generated by Yale Laboratory Medicine).

The abnormal population appeared to be highly enriched for the neoplastic T cell clone.
In seven of thirteen patients with detectable TCR-Vβ, enrichment of TCR-Vβ in the
abnormal population had a mean of 88% (range 66-95%) (Table C2, Figure C2).
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Table C2. TCR- Vβ and blood involvement characteristics of Vβ positive patients.
Lymphocytes with atypical phenotype refer to the population delineated by markers
shown in Table 1. Vβ panel of antibodies (ARUP) were used to assess relative
prevalence of T cells expressing each of these markers, specifically within the atypical
populations. In patients with low tumor burdens, such as patient 1, the percentage of Vβ
in total lymphocytes is 23% vs. in 91% in the atypical population, showing that this
population is highly enriched for the neoplastic clone.

Figure C2. Immunophenotypic analysis of the peripheral blood specimen from
patient 1 performed by ARUP laboratories. Abnormal population (CD3dim, CD4dim,
CD8-) is 25 % of lymphocytes, and of that population, 91% express TCR Vβ 20. This
finding meets the criteria for T-cell monoclonality. The other T cell subsets (bright
CD3+, CD4+) show levels of TCR- Vβ expression close to or within normal range.
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In patients without the presence of an obvious TCR-Vβ clone, we have nevertheless been
able to identify the presence of a phenotypically abnormal population with alterations in
multiple similar T cell markers (Table C1). While the markers were variably lost from
patient to patient, within each individual the phenotypically abnormal lymphocyte
population retained consistent immunophenotype. For example, the abnormal population
in Patient 2 was consistently CD3dim, CD4dim, CD7- and CD26- over 12 months (data
not shown). The use of CD3, CD4, CD7 and CD26 facilitated the identification of the
abnormal population in two patients who did not meet criteria using CD7 and CD26
alone based on ISCL criteria.122

Leukemic CTCL can mimic a number of other erythrodermic conditions clinically,
including severe psoriasis, atopic dermatitis, GVHD and pityriasis rubra pilaris.
Diagnosis can be facilitated by the identification of specific peripheral blood findings,
such as an increased CD4/CD8 ratio, aberrant expression or loss of CD26 and CD7, as
well as T cell clonality as determined by Vβ testing.123-126 However, due to only
moderate sensitivity and specificity offered by the commonly used markers, the diagnosis
Sézary syndrome using any single marker remains unsatisfactory.123,124,127 The addition
of T cell receptor Vβ chain antibodies, especially when analyzed on gated T cells with an
aberrant immunophenotype, improved detection sensitivity for the neoplastic clone as
well as for the monitoring of tumor burden; however T cell clonality can occur under
reactive, nonmalignant conditions and patients can have neoplastic proliferation without
an identifiable Vβ chain.124,128-130 Therefore, the accurate diagnosis of Sézary syndrome
likely relies upon the usage of multiple markers on flow cytometry, and our results reflect
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added benefits of assessing for aberrant CD2, CD3, CD4, CD5 and CD45RA/RO
expression, particularly in patients with low tumor burden.131,132

Limitations of this study include the small sample size, sampling from a single academic
center, as well as the lack of extension to clinical status and disease prognosis. This
project is being extended to involve larger numbers of patients with lengthier follow-up,
and data on clinical status and treatment response will be collected towards the goal of
establishing more sensitive criteria for the diagnosis and monitoring of tumor burden.
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